当前位置: X-MOL 学术Drug Resist. Updat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The prospects of tumor chemosensitivity testing at the single-cell level
Drug Resistance Updates ( IF 24.3 ) Pub Date : 2020-12-20 , DOI: 10.1016/j.drup.2020.100741
Chuan Yang 1 , Caibo Yang 2 , Yosef Yarden 3 , Kenneth K W To 4 , Liwu Fu 5
Affiliation  

Tumor chemosensitivity testing plays a pivotal role in the optimal selection of chemotherapeutic regimens for cancer patients in a personalized manner. High-throughput drug screening approaches have been developed but they failed to take into account intratumor heterogeneity and therefore only provided limited predictive power of therapeutic response to individual cancer patients. Single cancer cell drug sensitivity testing (SCC-DST) has been recently developed to evaluate the variable sensitivity of single cells to different anti-tumor drugs. In this review, we discuss how SCC-DST overcomes the obstacles of traditional drug screening methodologies. We outline critical procedures of SCC-DST responsible for single-cell generation and sorting, cell-drug encapsulation on a microfluidic chip and detection of cell-drug interactions. In SCC-DST, droplet-based microfluidics is emerging as an important platform that integrated various assays and analyses for drug susceptibility tests for individual patients. With the advancement of technology, both fluorescence imaging and label-free analysis have been used for detecting single cell-drug interactions. We also discuss the feasibility of integrating SCC-DST with single-cell RNA sequencing to unravel the mechanisms leading to drug resistance, and utilizing artificial intelligence to facilitate the analysis of various omics data in the evaluation of drug susceptibility. SCC-DST is setting the stage for better drug selection for individual cancer patients in the era of precision medicine.



中文翻译:

单细胞水平肿瘤化学敏感性检测的前景

肿瘤化学敏感性测试在以个性化方式为癌症患者优化选择化疗方案方面发挥着关键作用。已经开发了高通量药物筛选方法,但它们未能考虑到肿瘤内的异质性,因此只能对个体癌症患者的治疗反应提供有限的预测能力。最近开发了单癌细胞药物敏感性测试 (SCC-DST) 来评估单细胞对不同抗肿瘤药物的可变敏感性。在这篇综述中,我们讨论了 SCC-DST 如何克服传统药物筛选方法的障碍。我们概述了 SCC-DST 的关键程序,负责单细胞生成和分选、微流控芯片上的细胞药物封装以及细胞药物相互作用的检测。在 SCC-DST 中,基于液滴的微流体正在成为一个重要的平台,它集成了针对个体患者的药物敏感性测试的各种测定和分析。随着技术的进步,荧光成像和无标记分析已被用于检测单细胞药物相互作用。我们还讨论了将 SCC-DST 与单细胞 RNA 测序相结合以解开导致耐药性机制的可行性,并利用人工智能促进各种组学数据在药物敏感性评估中的分析。SCC-DST 正在为精准医疗时代为个体癌症患者更好地选择药物奠定基础。随着技术的进步,荧光成像和无标记分析已被用于检测单细胞药物相互作用。我们还讨论了将 SCC-DST 与单细胞 RNA 测序相结合以解开导致耐药性机制的可行性,并利用人工智能促进各种组学数据在药物敏感性评估中的分析。SCC-DST 正在为精准医疗时代为个体癌症患者更好地选择药物奠定基础。随着技术的进步,荧光成像和无标记分析已被用于检测单细胞药物相互作用。我们还讨论了将 SCC-DST 与单细胞 RNA 测序相结合以解开导致耐药性机制的可行性,并利用人工智能促进各种组学数据在药物敏感性评估中的分析。SCC-DST 正在为精准医疗时代为个体癌症患者更好地选择药物奠定基础。并利用人工智能促进各种组学数据在药敏评价中的分析。SCC-DST 正在为精准医疗时代为个体癌症患者更好地选择药物奠定基础。并利用人工智能促进各种组学数据在药敏评价中的分析。SCC-DST 正在为精准医疗时代为个体癌症患者更好地选择药物奠定基础。

更新日期:2020-12-30
down
wechat
bug